Introduction {#s1}
============

A critical step in the development of any new therapeutic agent is establishment of the optimal dosage and route of administration (ROA). This can be especially challenging when the treatment is a biologic agent that might exert its therapeutic effects via complex or poorly understood mechanisms. The Food and Drug Administration Center for Biologics Evaluation and Research *Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products*, November 2013, has recommended preclinical proof of concept studies that include (a) determination of the pharmacologically effective dose range (defined as the minimally effective and optimal doses); (b) optimization of the ROA with confirmation that the product reaches the target anatomic site; (c) optimization of the timing of administration relative to disease onset; (d) optimization of the dosing schedule; and (e) characterization of the putative mechanism of action. Additional studies to determine potential toxicity in animals and in vitro assays to evaluate biologic activity and potential safety issues are also strongly encouraged.

The purpose of the present review is to summarize what has been learned regarding the optimal cell dosage and ROA from preclinical and clinical studies of stem cell therapy for heart disease and to offer a perspective on future directions. Although it might seem reasonable to expect that the number of cells administered would be proportionate to the observed clinical effect, the data that has arisen from a relatively small number of studies has yielded conflicting and paradoxical results ([Fig. 1](#F1){ref-type="fig"}). Importantly, the expected direct relationship between cell dose and clinical effect has not been consistently observed and, in fact, some studies have shown inverse dose-response effects. These findings raise challenges regarding planning increasingly complex clinical trials.

![Different doses and/or concentrations and routes of administration have been used in various preclinical and clinical studies for ischemic cardiomyopathy, which have led to inconsistent findings.](sctm_20150101_f1){#F1}

Preclinical Studies {#s2}
===================

Preclinical studies addressing the dose range for cell therapy have yielded paradoxical findings. Halkos et al. \[[@B1]\] studied swine treated with three intravenous doses (1, 3, or 10 million) of allogeneic mesenchymal stem cells (MSCs) after a 75-minute left anterior descending coronary artery occlusion and found that the higher dose groups (3 and 10 million cells) had significantly improved left ventricular systolic function and preload-recruitable stroke work compared with the control group. In contrast, Hamamoto et al. \[[@B2]\] performed a dose-escalation study of sheep using four different doses (25, 75, 225, or 450 million allogeneic STRO-3-positive mesenchymal precursor cells) vs. cell media, administered intramyocardially at the infarct border zone, 1 hour after experimental acute myocardial infarction (AMI). Compared with the control group, only the lower (25 and 75 million) cell doses significantly attenuated infarct expansion and remodeling, reducing the left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) and improving the left ventricular ejection fraction (LVEF) at all cell doses ([Table 1](#T1){ref-type="table"}). Interestingly, the dose ranges used in the two studies did not overlap. It is also significant that the ROAs were different (intravenous vs. intramyocardial), and it is reasonable to surmise that this would influence the effects of the cell dose.
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Schuleri et al. \[[@B3]\] in a study delivering cells via direct injection in open chest pigs reported a significant reduction in infarct size with "high dose" (200 million) autologous MSCs compared with "low dose" (20 million) autologous MSCs in post-AMI swine. Regional contractility, as assessed by tagged magnetic resonance imaging-derived circumferential shortening, improved in both groups, although the contractility of the infarct zone improved only in the higher dose group. In contrast to these findings, Hashemi et al. \[[@B4]\], using endomyocardial delivery, found that the lower dose MSC groups (24 and 240 million) exhibited a significant decrease in infarct size, but the higher dose group of 440 million MSCs did not.

Summarizing, the foregoing preclinical studies varied in design, ROA, and the results related to cell dose. The range of total cell numbers used in each study differed significantly, and the definitions of "low" versus "high dose" were inconsistent. Of particular importance, the effects of cell concentration and total injection volume also remain to be elucidated as they relate to the various routes of administration being used (discussed below). Thus, whether a "low" or "high" dose is most efficacious in reducing the infarct size and improving cardiac structure and function remains unknown.

Clinical Studies {#s3}
================

Three clinical trials have evaluated the relationship between cell dose and clinical benefit. Quyyumi et al. \[[@B5]\] administered autologous bone marrow CD34^+^ cells to patients with an ST-elevation MI. The cells were infused by an intracoronary route into the infarct-related artery 8 days after stenting and three different cell doses (5, 10, or 15 million) were studied. Patients who received ≥10 million CD34^+^ cells demonstrated a significant improvement in perfusion, as measured by single-photon emission computed tomography, and a trend toward improved LVEF in those receiving 5 million CD34^+^ cells compared with the control. In contrast, Losordo et al. \[[@B6]\] evaluated 24 patients who had received one of three dose cohorts (5 × 10^4^, 1 × 10^5^, or 5 × 10^5^ per kilogram autologous CD34^+^ cells) in a phase I to IIa, double-blinded, placebo-controlled, randomized clinical trial, and no dose-response relationship was observed. However, in a larger trial \[[@B6]\] by the same group, 167 patients were randomized to one of two doses (1 × 10^5^ per kilogram or 5 × 10^5^ per kilogram autologous CD34^+^ cells or an equal volume of placebo), and the low-dose group experienced a significant improvement in angina frequency and exercise tolerance. Finally, in the PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis (POSEIDON) trial \[[@B7]\], Hare et al. randomized 30 patients to six subgroups according to the source of the cells (allogeneic vs. autologous) and the dose (20 million, 100 million, or 200 million cells). All patients received ten 0.5-ml injections transendocardially via catheter. Compared with the 200 million cell dose group, the patients who received 20 million cells were found to have significantly greater LVEF, improvement in LVESV, and a reduction in scar size, as measured by early enhancement ([Table 2](#T2){ref-type="table"}).
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Thus, just as noted for the preclinical studies, clinical trials have reported inconsistent and conflicting results regarding the relationship between the cell dose and clinical benefit. It is also important to note that it might not be appropriate to make comparisons between cell dosing studies that have used different routes of administration. Furthermore, although many preclinical studies \[[@B8]--[@B11]\] and clinical trials \[[@B12]--[@B20]\] have examined other cell types, such as bone marrow-derived mononuclear cells (BMMNCs), c-kit^+^ cardiac stem cells, and cardiac CD105^+^ culture-expanded MSCs (cardiosphere-derived cells), they did not compare the cell doses but, rather, single doses with different cell products or placebo.

Route of Administration {#s4}
=======================

Studies evaluating both the cell dose and the ROA or compared intravenous administration directly with other routes have not yet been reported. We have summarized the three studies comparing intracoronary and transendocardial delivery.

Perin et al. compared intracoronary and transendocardial delivery of allogeneic MSCs in a canine model of AMI \[[@B21]\] and found that transendocardial injection improved LVEF, LVEDV, LVESV, and capillary density. However, intracoronary infusion did not \[[@B21]\]. In addition, transendocardial injection was associated with a greater reduction of myocardial ischemia. When both delivery techniques were assessed for cell retention, transendocardial injection yielded a higher MSC concentration per µm^2^ than did intracoronary infusion. Vrtovec et al. reported similar findings in patients with nonischemic cardiomyopathy, notable for increased myocardial cellular retention and improvements in short- and long-term ventricular function with transendocardial versus intracoronary delivery of CD34^+^ cells \[[@B22], [@B23]\]. In contrast, Rigol et al. compared intracoronary versus transendocardial administration of adipose tissue-derived stem cells in a porcine model of AMI and found that the intracoronary route significantly increased neovascularization compared with the transendocardial route, although both delivery modes resulted in similar rates of engraftment \[[@B24]\].

The intracoronary infusion of stem cells has certain logistical benefits, including its relatively less complex technique. However, it is limited by the inaccessibility of some myocardial distributions in many patients with advanced coronary artery disease. Perhaps most importantly, the potential for microvascular obstruction by the infused cells, which can result in myocardial necrosis, could limit the applicability of this technique for certain cell types. Nevertheless, to date, this is the most studied technique for cell delivery during the time of percutaneous coronary intervention after AMI \[[@B25]\]. Moreover, the SCIPIO (Cardiac Stem Cell Infusion in Patients With Ischemic Cardiomyopathy) trial demonstrated in patients with ischemic cardiomyopathy that intracoronary infusion of 1 million c-kit^+^ cardiac stem cells is safe and effective in improving left ventricular systolic function and reducing infarct size \[[@B12]\]. However, whether higher doses are safe or exert greater effectiveness is unknown. To this end, Keith et al. investigated the safety of delivering higher doses of human c-kit^+^ cardiac stem cells by intracoronary infusion in a porcine model. The investigators found that infusion of 20 million human c-kit^+^ cardiac stem cells does not lead to acute cardiac injury, impairment of cardiac function, or end organ damage \[[@B26]\].

Catheter-based transendocardial injection and direct surgical intramyocardial injection of MSCs have been investigated in various preclinical and clinical studies and were shown to be safe and effective \[[@B2], [@B3], [@B7], [@B27]--[@B36]\]. In an analysis from the POSEIDON clinical trial, transendocardial injection of MSCs reduced the scar size in both injected and noninjected myocardial segments; however, segmental contractility improved only in the injected scar segments. The increase in segmental contractility was greatest in those territories with severe baseline dysfunction \[[@B35]\].

Conclusion {#s5}
==========

An importnt issue defining any new effective therapy is to establish the optimal dose and delivery method. The use of living cells as therapeutic agents differs in many important ways from traditional pharmacology, for which well-established principles of pharmacokinetics and pharmacodynamics are operative. However, in the field of cell therapy for cardiovascular disease, these issues remain to be defined. For cell therapy, the appropriate quantity and/or concentration of the transplanted cells and the ROA are important; however, very different principles and assumptions might be involved in assessing the correct dosing regimens. Although it might seem intuitive that the raw number of cells administered would be proportionately related to their clinical effect, using the cardiac structure, functional capacity, and quality of life measurements as clinical parameters, this concept has not been established conclusively.

Despite an extensive body of data since the publication of the first clinical trials of stem cell therapy for heart disease in 2002 to 2003 \[[@B37]--[@B39]\], the specification of an optimal dosage and ROA for the various stem cell preparations remains an elusive goal. The factors contributing to this include (a) no rational basis for standardizing the broad variety of stem cell sources and production methods; (b) inadequate methods for determining the quality and potency or biologic activity of stem cell preparations; (c) a lack of studies comparing both cell dose and ROA; and (d) the heterogeneity of target indications and patients. Furthermore, to our knowledge, no systematic studies have been performed of the potential sources of error or variability, including (a) concentration-dependent cell aggregation, which might affect transendothelial migration and/or homing to injured myocardium; (b) vehicle-dependent effects on exposure of receptor or effector sites; and (c) needle bore-dependent effects on cell integrity resulting from excessive shear forces.

As noted, the available preclinical and clinical evidence is conflicting, with some studies reporting that a lower cell dosage and/or infusion cell concentration would provide the most benefit \[[@B2], [@B4], [@B7]\], and others finding either an inverse or nonlinear relationship \[[@B3], [@B40]\]. To our knowledge, no studies have evaluated both the cell dose and the ROA. Also, and perhaps importantly, no clinical trials have evaluated the cell dose for BMMNCs, cardiosphere-derived cells, or c-kit^+^ cardiac stem cells. Of note, a flat dose-response relationship for intracoronary c-kit^+^ cardiac stem cells was recently reported in a rat model of acute myocardial infarction \[[@B41]\]. It is also important to highlight that immune status, in relation to whether autologous or allogeneic stem cells are administered, might play a larger role than expected in the dose response \[[@B42]\]. A recent study by Premer et al. showed that allogeneic, but not autologous, MSCs increased endothelial progenitor cell colonies and restored flow-mediated vasodilation in patients with ischemic and nonischemic cardiomyopathy. The inconclusiveness of the published data on the optimal cell type, together with the potentially paradoxical effects of autologous versus allogeneic cell sources, further complicates matters, necessitating additional studies on these relationships before advancing to larger dose and ROA comparative trials.

Thus, the field of cell therapy for cardiovascular disease still lacks consistent and reliable dosage and ROA data that would inform safety and efficacy considerations. We encourage the scientific community to consider cell comparisons, dose-response assessments, and comparative ROA evaluations in their preclinical and clinical study designs.

Although the cell type, dosage, concentration, and delivery modalities are important considerations for regenerative cell therapy clinical trials, our survey of the published studies suggests that the available data are inconclusive and additional early phase studies could be needed before proceeding to pivotal clinical trials. At a minimum, investigators undertaking phase III trials should be mindful of any assumptions determined from studies of other cell types and/or ROAs and ensure that adequate attention has been given to these as yet incompletely understood variables.
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